SOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve breast cancer patient outcomes: Boston Wednesday, August 6, 2025, 13:00 Hrs [IST] SOPHiA GENETICS, a clo ...

Celcuity said on Monday its experimental combination treatment delayed the progression of a type of advanced breast cancer, sending the biotech firm's shares surging more than twofold in premarket ...

Pascal Soriot's comments came during AstraZeneca's Q2 earnings call in regard to President Donald Trump’s newly announced ...

Antibody-drug conjugates are currently being investigated in more than 260 clinical trials.“It’s going to be the next novel ...

Celcuity said on Monday its experimental combination treatment delayed the progression of a type of advanced breast cancer in a late-stage study, sending the biotech firm's shares surging to a record ...

AstraZeneca Plc and Daiichi Sankyo Co.’s Enhertu delayed the advance of a common type of breast cancer by more than a year in a large study, a result that may lead to expanded use of the medicine.

Common respiratory infections like COVID and the flu could awaken dormant breast cancer cells in the lungs and lead to ...

CHICAGO — Treating breast cancer patients with AstraZeneca’s experimental pill camizestrant at the first sign of resistance to standard treatments cut the risk of disease progression or death ...

Lynparza patients had a 79.6% IDFS rate at six years, compared to 70.3% for placebo patients, with the drug reducing the risk of invasive breast cancer recurrence, second cancers, or death by 35%.

AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly improve overall survival for patients with a type of breast cancer in a late ...

L ONDON — AstraZeneca said Friday an experimental drug tamped down the progression of a certain type of breast cancer in a Phase 3 trial, a win for the company after the same drug produced ...